[HTML][HTML] Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer
…, R Hui, T Csőszi, A Fülöp, M Gottfried… - … England Journal of …, 2016 - Mass Medical Soc
Background Pembrolizumab is a humanized monoclonal antibody against programmed
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …
death 1 (PD-1) that has antitumor activity in advanced non–small-cell lung cancer (NSCLC), …
[HTML][HTML] Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE …
…, JP Delord, R Geva, M Gottfried… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Genomes of tumors that are deficient in DNA mismatch repair (dMMR) have high
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …
microsatellite instability (MSI-H) and harbor hundreds to thousands of somatic mutations …
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, A Somfay, ÉS Ezer, A Telekes, J Bar, M Gottfried… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with PD-L1 tumor proportion …
…, R Hui, T Csőszi, A Fülöp, M Gottfried… - Journal of clinical …, 2019 - ascopubs.org
Purpose In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab
significantly improved progression-free survival and overall survival (OS) compared with …
significantly improved progression-free survival and overall survival (OS) compared with …
[HTML][HTML] Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score≥ 50%
…, R Hui, T Csőszi, A Fülöp, M Gottfried… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
… Robinson, MD, MSc, 3 Rina Hui, MBBS, PhD, 4 Tibor Csőszi, MD, 5 Andrea Fülöp, MD, 6
Maya Gottfried, MD, 7 Nir Peled, MD, PhD, 8 Ali Tafreshi, MD, 9 Sinead Cuffe, MD, 10 Mary …
Maya Gottfried, MD, 7 Nir Peled, MD, PhD, 8 Ali Tafreshi, MD, 9 Sinead Cuffe, MD, 10 Mary …
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind …
…, S Orlov, M Krzakowski, J von Pawel, M Gottfried… - The lancet …, 2014 - thelancet.com
Background The phase 3 LUME-Lung 1 study assessed the efficacy and safety of docetaxel
plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). Methods …
plus nintedanib as second-line therapy for non-small-cell lung cancer (NSCLC). Methods …
[HTML][HTML] Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III …
…, MM Awad, A Navarro, M Gottfried… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell
lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study …
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer …
…, PJ Souquet, D Moro-Sibilot, M Gottfried… - The Lancet …, 2021 - thelancet.com
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum–etoposide)
showed a significant improvement in overall survival versus platinum–…
showed a significant improvement in overall survival versus platinum–…
Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international …
…, R Hui, T Csőszi, A Fülöp, M Gottfried… - The Lancet …, 2017 - thelancet.com
Background In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred
longer progression-free survival than did platinum-based therapy in patients with treatment-…
longer progression-free survival than did platinum-based therapy in patients with treatment-…
[HTML][HTML] Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 …
…, JP Delord, B Gao, D Planchard, M Gottfried… - Journal of Thoracic …, 2020 - Elsevier
Introduction Pembrolizumab has shown clinical benefit in patients with previously treated
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806 …
recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806 …